As of Dec 05
| +0.49 / +2.94%|
The 13 analysts offering 12-month price forecasts for Myriad Genetics Inc have a median target of 18.00, with a high estimate of 42.00 and a low estimate of 16.00. The median estimate represents a +4.96% increase from the last price of 17.15.
The current consensus among 16 polled investment analysts is to Hold stock in Myriad Genetics Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.